2) .@heartdrsingh is faculty at both @MCG_AUG and College of Health Professions, Mercer University Atlanta. He is Director, Clinical Research at NSC Cardiology, Johns Creek, Georgia, and has been involved with the clinical development of #etripamil from the beginning. pic.twitter.com/MzP5VcMxwk
— cardio-met (@cardiomet_CE) November 10, 2025
4a) #Etripamil? Sound familiar? That’s because we’ve talked about it here before—like just after #ACC25: https://t.co/ulhUQUJrUm . Etripamil is a still-investigational #CCB, administered nasally, and is the first advance in self-administered #SVT treatment in many years! pic.twitter.com/XtG222KaJH
— cardio-met (@cardiomet_CE) November 10, 2025
4c) If I tell you that 1,107 pts in early trials received at least one TEST dose of #etripamil while in #sinus rhythm #SR to simulate real-world use, what do you think was the test dose failure rate (intolerance requiring discontinuation)?
— cardio-met (@cardiomet_CE) November 10, 2025
6a) What we saw at #AHA25 was a systematic review of randomized controlled trials #RCTs & open-label studies evaluating #etripamil in adult patients with ECG-documented PSVT. Those trials were:
— cardio-met (@cardiomet_CE) November 10, 2025
Phase 2: NODE-1 (double-blind RCT):
🔓 https://t.co/jrEvqeVbyt
(cont)
7) Short summaries:#NODE_301:
— cardio-met (@cardiomet_CE) November 10, 2025
70mg #etripamil, or a regimen using a repeat-dose if persistent sx 10 min after the first, self-administered outside the healthcare setting, converted #PSVT to #SR to a significant degree by 30 min. pic.twitter.com/BPTK995pMg
8b) 109/181 (60.2%) of #PSVT episodes converted to #SR w/self- administered #etripamil within 30min as did 75.1% w/in 60min. 21/26 (81%) pts whose PSVT was successfully terminated with etripamil during their 1st episode, also had success with etripamil during their 2nd episode.
— cardio-met (@cardiomet_CE) November 10, 2025
9a) #RAPID:
— cardio-met (@cardiomet_CE) November 10, 2025
The conversion efficacy of #etripamil vs placebo was 64% vs 31% (p<0.001) with a median time-to-conversion of 17.2 min vs 53.5 min, respectively.
Etripamil appeared to be safe, w/most AEs localized to 👃& were mild/mod & transient, but RAPID required . . .
10a) In #NODE_3, among the 151 pts who treated at least 2 episodes, 108 (71.5%) successfully converted #PSVT ➡️ #SR with etripamil by 60 min in the 1st episode, & of these, 87 (80.6%) converted with etripamil during their second episode (P=0.0019). pic.twitter.com/bWdEQ81zJY
— cardio-met (@cardiomet_CE) November 10, 2025
10c) … an UNsuccessful conversion w/#etripamil during an earlier episode was NOT predictive of later lack of conversion. Of 43 pts who did not convert to #SRduring their 1st episode, 24/43 (55.8%) still successfully #PSVT ➡️ SR during a subsequent etripamil-tx'd episode.
— cardio-met (@cardiomet_CE) November 10, 2025
11b) Safety data were descriptively summarized, focusing on #TEAEs within 24h of dosing (TEAE24h), serious AEs, & drug discontinuation due to AEs.
— cardio-met (@cardiomet_CE) November 10, 2025
12b) At 60 minutes post-administration, #etripamil conversion rates varied from 63.2% to 75.1% across individual studies, as illustrated in the KM curves.
— cardio-met (@cardiomet_CE) November 10, 2025
👉 The median time to conversion was 18.5 minutes (95% CI: 15.7 to 21.0 minutes). pic.twitter.com/16T0EiEnUy
13b) Common TEAEs (occurring in >5% of #etripamil-exposed patients) included nasal discomfort, nasal congestion, rhinorrhea, throat irritation, and epistaxis. pic.twitter.com/04qEMrVx3H
— cardio-met (@cardiomet_CE) November 10, 2025
14b) Test-dose failure, defined as intolerance requiring discontinuation, occurred in 16 patients (1.4%), primarily due to mild nasal symptoms that in fact resolved quickly pic.twitter.com/cXAlVQ4XWb
— cardio-met (@cardiomet_CE) November 10, 2025
16a) .@heartdrsingh, who IS one of the authors, adds comments: As this abstract illustrates, the consistency in both safety and efficacy across multiple trials strengthens our confidence that #etripamil will truly benefit patients with SVT. This is not just a chance finding.
— cardio-met (@cardiomet_CE) November 10, 2025
17) And that's it! You just earned 0.5hr 🆓CE/#CME! Just point your 🖱️to https://t.co/tDwN8ntEsq and claim your certificate. Thanks to @heartdrsingh for teaching us!
— cardio-met (@cardiomet_CE) November 10, 2025
You can always learn from the experts and earn 🆓CE/#CME 🇺🇸🇬🇧🇨🇦🇪🇺at @cardiomet_ce !!#AHA25 #AHA2025